We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integra LifeSciences to Offer aap's LOQTEQ System in the US
Read MoreHide Full Article
Global medical technology major, Integra LifeSciences Holdings Corporation (IART - Free Report) recently inked an agreement with aap Implantate AG, a Berlin-based trauma product maker. Under the deal, Integra LifeSciences will distribute aap’s LOQTEQ Distal Radius System in the U.S.
The LOQTEQ Distal Radius System features an advanced design with multiple plate options to provide a variety of fracture patterns, anatomies and instrumentation for intra-operative efficiency.
Integra LifeSciences’ management expects this alliance to enhance its portfolio and elevate its position to being a one-stop solution for patients’ wrist needs from fracture plating to fusion and arthroplasty. The company is also formulating strategies to gain traction in the market.
Also, according to management at aap, this collaboration will help the company expand its orthopedic foothold in the U.S. and accelerate growth for the companies.
According to transparency market research, the global orthopedic devices market is estimated to register a modest 4.90% CAGR during the forecast period, growing from a value of $29.2 billion in 2012 to $41.2 billion in 2019. Thus, the company has huge growth potential in this market.
We note that in the majority of the last three months, Integra Lifesciences has been trading above the Zacks categorized Medical - Biomedical and Genetics sub-industry. The stock has gained 12.2%, much better than the 7.4% decline of the broader industry.
Recent Developments
Integra LifeSciences recently made several strategic collaborations under its Orthopedics and Tissue Technologies segment. The company announced full commercial availability of its Cadence Total Ankle System, a new ankle prosthesis developed in partnership with four world leading foot and ankle surgeons.
Additionally, Integra LifeSciences entered into an exclusive distribution deal with Dr. Reddy's Laboratories Limited. Under the agreement, Dr. Reddy’s will market and distribute DuraGen Plus and Suturable DuraGen Dural Regeneration Matrices for use in patients in India.
Key Picks
Integra LifeSciences currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector are Luminex Corporation , Inogen, Inc. (INGN - Free Report) and Edwards Lifesciences Corporation (EW - Free Report) . Notably, Luminex and Inogen sport a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 8.5% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 77.8%.
Edwards Lifesciences has an expected long-term adjusted earnings growth of almost 15.6%. The stock added roughly 19.9% over the last three months.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Integra LifeSciences to Offer aap's LOQTEQ System in the US
Global medical technology major, Integra LifeSciences Holdings Corporation (IART - Free Report) recently inked an agreement with aap Implantate AG, a Berlin-based trauma product maker. Under the deal, Integra LifeSciences will distribute aap’s LOQTEQ Distal Radius System in the U.S.
The LOQTEQ Distal Radius System features an advanced design with multiple plate options to provide a variety of fracture patterns, anatomies and instrumentation for intra-operative efficiency.
Integra LifeSciences’ management expects this alliance to enhance its portfolio and elevate its position to being a one-stop solution for patients’ wrist needs from fracture plating to fusion and arthroplasty. The company is also formulating strategies to gain traction in the market.
Also, according to management at aap, this collaboration will help the company expand its orthopedic foothold in the U.S. and accelerate growth for the companies.
According to transparency market research, the global orthopedic devices market is estimated to register a modest 4.90% CAGR during the forecast period, growing from a value of $29.2 billion in 2012 to $41.2 billion in 2019. Thus, the company has huge growth potential in this market.
We note that in the majority of the last three months, Integra Lifesciences has been trading above the Zacks categorized Medical - Biomedical and Genetics sub-industry. The stock has gained 12.2%, much better than the 7.4% decline of the broader industry.
Recent Developments
Integra LifeSciences recently made several strategic collaborations under its Orthopedics and Tissue Technologies segment. The company announced full commercial availability of its Cadence Total Ankle System, a new ankle prosthesis developed in partnership with four world leading foot and ankle surgeons.
Additionally, Integra LifeSciences entered into an exclusive distribution deal with Dr. Reddy's Laboratories Limited. Under the agreement, Dr. Reddy’s will market and distribute DuraGen Plus and Suturable DuraGen Dural Regeneration Matrices for use in patients in India.
Key Picks
Integra LifeSciences currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector are Luminex Corporation , Inogen, Inc. (INGN - Free Report) and Edwards Lifesciences Corporation (EW - Free Report) . Notably, Luminex and Inogen sport a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 8.5% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 77.8%.
Edwards Lifesciences has an expected long-term adjusted earnings growth of almost 15.6%. The stock added roughly 19.9% over the last three months.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>